Upstream Bio, Inc. (NASDAQ:UPB) Receives $45.25 Average Price Target from Brokerages

Upstream Bio, Inc. (NASDAQ:UPB) has earned a consensus rating of “Moderate Buy” from the five ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have covered the stock in the last year is $45.25.

UPB has been the topic of several analyst reports. Mizuho upgraded Upstream Bio to a “strong-buy” rating in a research report on Thursday. Evercore ISI assumed coverage on shares of Upstream Bio in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $40.00 price target on the stock. Lifesci Capital initiated coverage on Upstream Bio in a research report on Tuesday, December 2nd. They set an “outperform” rating and a $43.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Upstream Bio in a research note on Wednesday, October 8th. Finally, Truist Financial assumed coverage on Upstream Bio in a report on Tuesday, October 14th. They set a “buy” rating and a $47.00 price target for the company.

Institutional Investors Weigh In On Upstream Bio

Several institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets raised its holdings in Upstream Bio by 229.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 3,097 shares of the company’s stock valued at $34,000 after buying an additional 2,158 shares during the period. Legal & General Group Plc boosted its stake in shares of Upstream Bio by 83.0% during the 2nd quarter. Legal & General Group Plc now owns 3,174 shares of the company’s stock worth $35,000 after purchasing an additional 1,440 shares during the period. CWM LLC boosted its stake in shares of Upstream Bio by 107.5% during the 2nd quarter. CWM LLC now owns 3,312 shares of the company’s stock worth $36,000 after purchasing an additional 1,716 shares during the period. Ameritas Investment Partners Inc. raised its holdings in shares of Upstream Bio by 95.3% in the second quarter. Ameritas Investment Partners Inc. now owns 3,558 shares of the company’s stock valued at $39,000 after acquiring an additional 1,736 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its holdings in shares of Upstream Bio by 1,963.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock valued at $57,000 after purchasing an additional 2,887 shares in the last quarter.

Upstream Bio Trading Down 1.7%

Shares of NASDAQ:UPB opened at $29.35 on Thursday. Upstream Bio has a 12 month low of $5.14 and a 12 month high of $33.00. The company has a 50-day moving average price of $25.33 and a 200-day moving average price of $18.54. The company has a market cap of $1.59 billion, a price-to-earnings ratio of -15.61 and a beta of 1.83.

Upstream Bio (NASDAQ:UPB) last announced its earnings results on Wednesday, November 5th. The company reported ($0.63) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.78) by $0.15. Upstream Bio had a negative net margin of 4,366.77% and a negative return on equity of 28.71%. The business had revenue of $0.68 million during the quarter, compared to the consensus estimate of $0.65 million. As a group, research analysts forecast that Upstream Bio will post -4.3 EPS for the current fiscal year.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.